Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pregnon is a new low-dosage ovulation-inhibiting agent containing 1 mg of lynestrenol and .05 mg of ethinyl estradiol in each tablet. It is also marketed under the name of Pregnon 28 or Ovostat 28 in which each package contains 22 active plus 6 placebo tablets. Data were collected from Belgian clinics and evaluated by the Medical Unit of Organon in Belgium and the Netherlands. During this study, 639 women of fertile age were monitored through 9159 cycles. The maximum period of treatment was 36 cycles. Clinical and gynecological examinations were made before treatment and then every 2 or 3 months. Treatment was begun by taking the 1st tablet on the 1st day of menstruation. After taking 22 tablets there was a 6-day tablet-free interval during which withdrawal bleeding usually occurred. The intensity of the withdrawal bleeding was normal in 57.3%, slight in 41.7%, and heavy in 1%. Spotting was noted in 3.1% of the cycles and breakthrough bleeding occurred in 2.9%. Usually they occurred in the first 3 cycles. Amenorrhea was observed in 2.9% of the cycles. Body weights were relatively unchanged. Blood pressures remained the same. Side effects were headache, nausea, vomiting, breast tenderness, heavy legs, leucorrhea, nervousness, depression, and decreased libido. Only 46 patients discontinued treatment because of these drug effects yielding an acceptability level of about 93%. Since no pregnancies occurred during this study, the Pearl index was 0.
 ...
PMID:Clinical evaluation of a new oral contraceptive, 'Pregnon'. 114 83

This report summarizes a meeting of the IPPF International Medical Advisory Panel (IMAP) held in November, 1986, at which information on steroidal oral contraception (OC), Acquired Immunodeficiency Syndrome (AIDS), and female sterility were discussed. Regarding the multiphasic OC now in use, the benefits to health and well-being outweigh the possible side-effects and infrequent complications. Use is associated with a lower incidence of pelvic inflammatory disease, 96-98% effective prevention of pregnancy, a protective effect against ovarian and endometrial cancer, and regulation of erratic menstrual cycles. Minor side effects include nausea, vomiting, dizziness, headache, fluid retention, and inter-menstrual spotting. Adverse effects are circulatory system disease, myocardial infarction, venous thromboembolism, elevated blood pressure, and liver disease. Data on possible carcinogenicity have been conflicting. For women over age 40 OCs should be prescribed with caution. IMAP also drew up recommendations to assist FPAs to play a more active role in controlling the spread of AIDS. An effective program of Information and Education is of primary importance, targeting family planning workers and clients, teachers, parents, and employers. Wide promotion of condom use is a priority. Studies in Africa have revealed a major epidemic of AIDS, with the major mode of transmission heterosexual. The only immediate practical step in prevention of spread is by changes in sexual behavior. The last topic discussed is that of sterility in African women. The naturally occurring level of infertility expected in all populations of women is 3%; high levels in Africa vary by region from 3-32%. These levels of sterility are acquired through infection with Neisseria gonorrheae and Chlamydia trachomatis. Silent infection of women with Chlamydia make treatment especially difficult.
 ...
PMID:Statement on steroidal oral contraception. 1234 Sep 76

The mechanical dilation of the cervix during induced abortion may cause pain and trauma. A clinical trial was conducted to investigate the effectiveness of applying a hydrophilic polyurethane dilation rod to the cervix to soften tissue and dilate the cervix before the induced abortion. 100 healthy pregnant women aged 19-34 were screened and recruited into the study. The duration of pregnancy ranged from 5.9-12 weeks. The study had 2 purposes: 1) to identify the shortest duration of application of the rod for dilating the cervix and 2) to compare the effectiveness of applying the rod for 1/2, 1, and 2 hours. The study found that the use of the hydrophilic polyurethane rod and a significant effect on dilating the cervix. The effectiveness of the rod application of 2, 3, 6, and 12 hours was similar. The dilation was sufficient except in a few cases. 21-47 of the patients who use the rods for 1 hour and 1/2 hour, respectively, needed additional dilation. The dilation was much easier than it would have been without using the rods. Among all the groups of the rod users, no spontaneous abortion and hemorrhage occurred. Spotting, nausea, and vomiting were observed in a few women. The study results showed that the hydrophilic polyurethane rod is a safe, effective, and economical method of cervix dilation for induced abortion. It can reduce pain, the time needed for suction, and blood loss. The only inconvenience of the method is the increased amount of work. The method is especially attractive to first-time pregnant women, and its use may be expanded in outpatient clinics.
 ...
PMID:[The application of hydrophilic polyurethane rod before vacuum aspiration]. 1234 6